Literature DB >> 24315314

Cerebral aspergillosis in adult critically ill patients: a descriptive report of 10 patients from the AspICU cohort.

Herbert Spapen1, Jerrold Spapen2, Fabio S Taccone3, Wouter Meersseman4, Jordi Rello5, George Dimopoulos6, Pierre-Emmanuel Charles7, Ratna Rao8, Marcos Pérez5, Claude Martin9, Dirk Vogelaers10, Stijn I Blot11.   

Abstract

An unexpectedly high incidence of invasive pulmonary aspergillosis (IPA) has been reported in non-neutropenic intensive care unit (ICU) patients. After the respiratory tract, the brain is most often affected by invasive aspergillosis. However, little is known about brain involvement by Aspergillus in critically ill patients. In this study, demographics, risk profile, diagnosis, treatment and outcome of proven cases of invasive cerebral aspergillosis (ICA) taken from a cohort of 563 adult patients with evidenced Aspergillus involvement during their ICU stay were reviewed. Ten patients with central nervous system aspergillosis were identified. All had one or more host factors predisposing for invasive aspergillosis. The clinical and radiological presentation was non-specific and exclusively pulmonary-related. All but one patient had proven or probable/putative IPA. On cerebral computed tomography, lesions appeared as either solitary and hyperdense or were multiple and randomly distributed throughout the brain. One patient presented with sole meningeal infestation. Aspergillus infection was confirmed by brain biopsy in three subjects. Voriconazole was used as primary treatment in only one-half of the patients. Mortality was 90%. ICA is not frequently observed in adult ICU patients. Diagnosis must be considered in patients at risk presenting with proven or probable/putative IPA in association with suggestive neuroradiological findings. The brain is most likely affected through haematogenous dissemination from the lungs. Current treatment recommendations are not always applied and outcome remains dismal.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Aspergillus; Cerebral aspergillosis; Diagnosis; Intensive care unit; Invasive pulmonary aspergillosis; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24315314     DOI: 10.1016/j.ijantimicag.2013.10.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid.

Authors:  François Réminiac; Romain Sonneville; Laurent Massias; Christian Chochillon; Michel Wolff
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

2.  Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes.

Authors:  Fabio Silvio Taccone; Anne-Marie Van den Abeele; Pierre Bulpa; Benoit Misset; Wouter Meersseman; Teresa Cardoso; José-Artur Paiva; Miguel Blasco-Navalpotro; Emmanuel De Laere; George Dimopoulos; Jordi Rello; Dirk Vogelaers; Stijn I Blot
Journal:  Crit Care       Date:  2015-01-12       Impact factor: 9.097

3.  Isolated cerebral aspergillosis in an immunocompetent woman on treatment for bacterial infected necrotizing pancreatitis: A case report.

Authors:  Shaoyang Zhang; Qinghui Fu; Qi Chen; Ting-Bo Liang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

4.  Unusual manifestation of COVID-19-associated pulmonary aspergillosis: A case report.

Authors:  Maryam Albaji; Mohammad Reza Fattahi; Arad Iranmehr
Journal:  Clin Case Rep       Date:  2022-08-11

5.  Central Nervous System Aspergilloma in an Immunocompetent Patient: A Case Report.

Authors:  Hasanreza Mohammadi; Sohrab Sadeghi; Shokrollah Zandi
Journal:  Iran J Public Health       Date:  2015-06       Impact factor: 1.429

6.  Central nervous system aspergillosis in immunocompetent patients: Case series and literature review.

Authors:  Yubao Ma; Wanjun Li; Ran Ao; Xiaoyang Lan; Yang Li; Jiatang Zhang; Shengyuan Yu
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.